dencatistat

Dencatistat (formerly known as STP938) is a first-in-class, highly selective, orally bioavailable small molecule inhibitor of cytidine triphosphate synthase 1 (CTPS1), an enzyme essential for the de novo synthesis of pyrimidines. By selectively inhibiting CTPS1, dencatistat blocks the production of cytidine triphosphate (CTP), thereby disrupting DNA and RNA synthesis in rapidly proliferating cells such as lymphocytes and cancer cells. This leads to inhibition of cell proliferation and induction of apoptosis. Dencatistat demonstrates over 1,300-fold selectivity for CTPS1 over its homolog CTPS2, minimizing effects on non-hematopoietic tissues. The drug is being developed by Step Pharma primarily for the treatment of relapsed or refractory T-cell and B-cell lymphomas, with additional clinical development underway in advanced solid tumors—particularly those with loss of CTPS2—as well as preclinical evidence supporting potential use in autoimmune diseases like rheumatoid arthritis[4][5][6][7].

Brand names

dencatistat

Other names

dencatistat